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                                                  Introduction  
               Systemic lupus erythematosus (SLE) is the prototype autoimmune disease 
with varied clinical manifestations due to involvement of a variety of organ systems 
simultaneously or serially over a period of time. Similar to other rheumatic diseases 
the disease activity has to be controlled and maintained in a state of remission or low 
activity. Hence we have to monitor the disease activity periodically and adjust the 
dosage of medications.
1
  
              The disease can be either in a state of remission or can be chronically 
active or can be of remitting and relapsing type with intermittent flares . For 
measuring the disease activity, we do a clinical assessment followed by laboratory 
investigations. Some of the immunological investigations like anti ds DNA and 
complements are still not affordable by everybody in a country like ours. The very 
purpose of this study is to look for other alternatives which can indirectly gauge the 
disease activity during a flare. 
              In SLE, cardiovascular system is equally affected like any other system.  
Even though the incidence of overt manifestations might be less common compared 
to other organs, at autopsy the incidence was found to be more.
2
Among the various 
causes of death in SLE, it is the third common cause. QT interval parameters have 
been found to point towards increased risk of death due to a cardiovascular cause 
and also helps in assessing the prognosis clinically.
2
 The purpose of this study is to 
identify whether QT interval calculation helps to assess the disease activity 
indirectly at baseline and during flares and hence indirectly the prognosis and 
cardiovascular risk. 
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          Among the QT interval parameters we have corrected QT interval (QTc) 
which when prolonged has been found to cause ventricular tachyarrythmias and 
sudden cardiac death. Similarly QT dispersion (QTd) which is the variability of QT 
interval from lead to lead in a single person has been found to be related wi th 
unstable electrical activity and arrhythmias of ventricles.
3
 By calculating the QT 
interval parameters we can find out the risk of cardiac death, its correlation with 
disease activity and its use as a surrogate marker. The conduction system 
involvement can also be the cause for these cardiac events. Anti Ro & La antibodies 
have been found to have relation in neonates with various cardiac manifestations but 
no strong association has been found in adults.
4 We also wanted to find its 
correlation with QT interval parameters and the disease activity.  
                 During our daily management we found that Erythrocyte Sedimentation 
Rate (ESR) has been found to increase with disease activity. But it has remained 
controversial. Hence we wanted to confirm it in our study as it could be the cheapest 
and readily available surrogate marker ever. Similarly serum uric acid levels were 
also higher in SLE patients at diagnosis irrespective of renal failure and its 
correlation with disease activity is also part of the study. Cutaneous involvement is 
one of the commonest manifestations in SLE. Most of our patients have cutaneous 
manifestations at presentation and also worsening during flares.  Whether cutaneous 
activity indirectly indicates the overall severity of autoimmunity and hence the 
disease activity in SLE patients is a thought provoking issue. Though there are 
various activity indices for skin we used the Cutaneous Lupus Erythematosus Disease 
Area and Severity Index (CLASI) in this study. Simlarly many disease activity indices 
are there to calculate the same in SLE but in this study we use SLEDAI which is 
simple to use clinically and has been tested in various clinical trials . 
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Aim 
To study the correlation between QTc interval parameters and disease activity in 
patients with SLE 
Primary objectives : 
1. To study the correlation between QT interval parameters (QTc interval & QT 
dispersion) and disease activity in patients with SLE. 
2. To study QT interval parameters during episodes of flare (on follow up). 
Secondary objectives : 
1. To study the correlation between QT interval parameters & auto antibodies. 
2. To study the correlation between ESR and disease activity (SLEDAI). 
3. To study the correlation between serum uric acid and disease activity (SLEDAI). 
4. To find out the correlation between CLASI and disease activity (SLEDAI) in 
patients with cutaneous manifestations of SLE. 
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                                      Review of literature 
                SLE is the typical autoimmune disease with varied manifestations 
involving all organ systems. The disease activity in SLE is a chronic ongoing one 
with intermittent relapses and remissions. If the disease activity is not controlled 
early it will lead on to organ damage with chronic morbidity or mortality if severe. 
Like other autoimmune diseases no single etiology exists and needs multiple factors 
for development of the disease. There is interaction between both environmental and 
genetic factors which might be single or multiple. The natural history of disease is 
depicted in the diagram below.
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Pathogenesis: The main mechanism in SLE is mounting of immune response against 
self nuclear antigens. Initially there is a nonspecific viral infection or some other 
environmental agent causing cell injury and apoptosis. The apoptotic material is 
presented by antigen presenting cells (mainly dendritic cells) to T cells. The B cells 
are activated in turn by these T cells. The cytokines and cell surface molecules 
involved are IL-10, 23 and CD 40L, CTLA-4. Other than this T cell dependent 
mechanism there exists a T cell independent one where B cell receptor & Toll like 
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receptor aids in activation of B cells.  Below is a diagrammatic representation of the 
pathogenesis in SLE.
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Cardiovascular System (CVS) and Lupus:  
The classic manifestations of SLE like cutaneous, renal etc. are being managed 
better now and hence CVS manifestations has become one of the major causes for 
morbidity and mortality. SLE with high disease activity, dosage of steroid used and 
disease duration are the factors definitely contributing to increased cardiovascular 
events and dysfunction of endothelium subclinically.
7-10
 The main cytokine which 
favours  atherogenesis and dysfunction of endothelium in lupus patients are Type I 
interferons.
11
 Neutrophil Extracellular Traps (NETs) formation leads to extrusion of 
chromatin and granular material outside the cell and might be the initial step of 
atherogenesis and also in causing dysfunction of the endothelium.
1
 The various 
cardiac manifestations are Pericarditis (the most common) with or without 
pericardial effusion, myocarditis, endocarditis, coronary vascular disease & 
conduction system abnormalities.  
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            Myocarditis is seen clinically in only 10% of patients but seen in 50% on 
autopsy studies.¹² When a SLE patient presents with conduction defects, 
arrhythmias, unexplained cardiomegaly or tachycardia, then myocarditis has to be 
suspected. Since myocardial involvement may not be overt it has to be detected with 
ECG (74% abnormality), ECHO (72% abnormality) or CXR (55 % abnormality). 
Newer modalities like Thallium scan, Cardiac MRI, SPECT can also identify 
abnormalities. There are also studies showing association of anti Ro and anti La auto 
antibodies with myocarditis.
13-16 
Other than these manifestations there can be 
dysfunction of autonomic nervous system which is more common in older women 
who attained menopause & those with peripheral nerve disease, systemic 
hypertension & cerebrovascular accident. They can also have atrioventricular blocks 
& less variation of periodic heart rate.
17,18 
 In general sudden cardiac death secondary to rhythm and conduction disturbances 
are more in autoimmune rheumatic diseases. The reason for arrhythmias are du e to 
re entry and due to altering or triggering of automaticity. In SLE the major cause for 
sinoatrial or atrioventricular node dysfunction is due to vasculitis of small vessels 
and granular or fibrous infiltration of nodes.
19
 In 34-70% of patients conduction 
abnormalities can be secondary to myocarditis.
20
 Usually they have a transient first 
degree heart block and rarely complete heart block (associated with anti U1RNP 
antibodies rather than anti Ro antibodies).²¹In contrast, conduction defects with 
myocarditis is more correlated with anti Ro antibodies and they are reversible on 
controlling the disease. 
                In a study done by Josiane Bourre Tessier et al the QT interval 
prolongation was associated with the presence of anti Ro antibodies.⁴ In another 
study done by Logar D et al they found that conduction abnormalities and 
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myocarditis were more common in SLE and had an association with anti Ro 
antibodies.
14 
               In a prospective study carried out by Moacir Fernandes de Godoy et al 
“patients with confirmed diagnosis were analyzed over a period of 13 years and 
concluded that there is cardiac impairment which keeps progressing and some even 
needed interventional procedures like angioplasty and emphasized the need for a 
meticulous cardiac follow up on a long term basis in patients with lupus”.22 
QT interval :  
                 Measurement of QT interval is important as both increase or decrease in 
QT beyond normal variation leads to sudden arrhythmias and acute cardiac death. As 
per Ilan Goldenberg et al. we have various computerised methods to assess QT 
interval like “individual-based corrections for repolarization duration, quantitative 
assessment of repolarization morphology, correction for repolarization dynamicity 
and analysis of repolarization variability.” But in this study we have used the manual 
determination method otherwise called as eyeball method or caliper method. Other 
than this it can be calculated manually by digitizing or on screen calculation in a 
computer.
23 
                 The automatic methods are not accurate most of the time and should be 
followed by a manual reading. But the best method is to record the ECG and display 
it on the screen of a computer or to scan the recorder ECG and then measure it on 
the screen with computer based calipers. It is the ideal method recommended as it 
provides ECG with high quality. 
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Usually the speed at which ECG is recorded is 25 millimeter per second with an 
amplitude of 10 millimeter per mill volt. With manual measurement, the level of 
accuracy of calculation is 20 to 40 milliseconds.  The QT interval value is calculated 
as a mean of three to five cardiac cycles and measured from where QRS complex 
starts to where T wave ends. Measurement of QT interval is made in lead II & 
V5/V6 and the value which is longest is chosen.
23 
How to overcome the practical difficulties in measuring QT interval?  
               The difficulty is to correctly identify the T wave with its descending limb 
intersecting the isoelectric line and when U waves are nearby the T wave. We then 
identify the descending limb of T wave intersecting with TP baseline (provided there 
is no U wave succeeding the T wave or when both waves can be identified 
separately). When the T wave is biphasic we usually take the point of final return of 
the T wave. QRS interval can be altered sometimes due to conduction blocks or 
drugs. The accurate duration of repolarization can‟t be measured and the JT interval 
has to be measured. The „S wave off point‟ to end of T wave is measured as JT.24 
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Figure A: Normal T wave morphology 
Figure B: Presence of U wave 
Figure C: Presence of biphasic T wave 
Figure D: Presence of T2 wave (another repolarization wave with a low amplitude) 
How to adjust for heart rate? 
All the ECG intervals vary with the heart rate i.e R-R interval. We have to correct 
for the heart rate to calculate the duration of repolarization.  We have various 
methods or formulae to correct for the QT interval with reference to a predicted 
value (calculated with a 60 per minute heart rate).All these formulae have been 
obtained from ECGs in resting state and need a normal sinus rhythm with no sudden 
fluctuations. By correlating between the QTc intervals obtained with a formula and 
the RR intervals we can assess the way in which a formula has performed. The 
correction formulae are not really successful unless we get a value which doesn‟t 
differ from zero and most of the formulae used actually don‟t. Here in the table 
below we have the various formulae used for calculation.
24 
 
The most common formula used clinically is the Bazett‟s formula. The corrected QT 
interval is calculated by dividing the QT interval (in seconds) by the RR interval   
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(in seconds) preceding it. With a faster heart rate it may overcorrect and it may 
under correct with a slower heart rate. For an ECG with fast heart rate the Frideri cia 
formula corrects accurately. From the Framingham study the linear formula was 
derived. No uniform opinion is available on the formula which can be used in 
clinical practice. But with heart range in normal limits (60-90/min) most of the 
formulae give similar results.
23 
How to calculate for ECGs with sinus arrhythmias ? 
              We need advanced methods to evaluate repolarization dynamics in ECGs 
with no stable heart rate. QT hysteresis/Lag is the adaptation of QT interval to heart 
rate changes with a delay. The adaptation of QT interval to accelerations is  faster 
than decelerations. Hysteresis is the QT versus RR interval plot representing the 
dynamic changes with respect to the heart rate and forms a loop. It is a highly 
individualized pattern.
23 
What are the normal values of QT interval? 
                As discussed above, the Bazett‟s formula is used most often and all the 
reference values for QT intervals are based on that formula. Based on a study done 
in 581 healthy subjects (included adult males, adult females and children) a set of 
values have been described to detect QTc prolongation and is mentioned in the t able 
below.
25 
 
11 
 
How repolarization morphology helps in calculation ?  
              By using measurements like T wave symmetry, area under T wave and 
interval from where T wave ends to peak of T wave (maximum amplitude) we can 
quantify repolarization. But it needs a specific software on computer and the ECG 
data has to be stored electronically. By visually assessing the T wave and its 
repolarization pattern we can can place it under the specific software category for 
assessment. For example, in patients with different types of long QT genotypes 
different patterns of T waves were observed.
26
 In type I usually we have a T wave 
which is broad based, single, uniform and at times T waves with late onset but 
normal morphology are also seen. In type II T waves with bifid morphology are 
seen. In type III, T waves are peaked, prominent and has a late onset.
26 
“Teach the tangent” method: It is otherwise called as „avoid the tail method‟. It is 
used mainly for ECGs with atypical T waves. The method was tested on a group of 
151 medical graduates and they achieved a diagnostic accuracy of 77% which was 
far better than the accuracy of cardiologists and non cardiologists using normal 
methods.
27, 28 
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Other methods like Holter monitoring and exercise testing can also be used to assess 
ventricular repolarization but these methods have not been standardized for primary 
assessment of ventricular repolarization. For events which occur very rarely in a day 
the Holter monitoring is of immense use but data obtained from an ECG and Holter 
can‟t be compared directly. For exercise tests a standard protocol is followed to 
assess the QT interval during periods of exercise and recovery.  
On long term following up of patients over years when ECG is repeated for an 
individual the QT interval differs substantially. So for abnormal values it is better to 
take multiple ECGs rather than a single ECG.
23-26 
In a study by Viskin S et al, “calculation of QT intervals manually was correct 96% 
of times when done by QT experts, 62% by arrhythmia experts and only less than 
25% by cardiologists and others.” But still, simple methods of assessing QT interval 
in routine ECGs helps us to assess the ventricular repolarization , provided we have a 
criteria which uniformly assesses the offset of T wave, heart rate correction and 
morphology of T wave.
27-30 
QT dispersion(QTd): 
                 As we discussed above, the QTc measurement was considered to reflect 
the repolarization of ventricles. Later it was found that the QT interval varied 
between different leads. So the difference between maximum and minimum QT 
interval was calculated and named as QT dispersion. It was found to be a fine marker 
of increased ventricular vulnerability to arrythmias.
31-33
  
                Initially the concept of QT dispersion was quite reasonable and many a 
time the association between arrhythmias and ventricular recovery time was 
13 
 
proved.
29,34,35 
It was thought that ventricular recovery time and its dispersion was 
reflected by QTd. A high degree of correlation was established between intracardiac 
monophasic action potentials and the QTd parameters. The ventricular recovery time 
heterogeneity is reflected by QTd and a value in the range of 70-120 ms can predict 
the increased risk for arrhythmias. 
       As discussed above, both manual and computer based methods are prone for 
errors. The main cause is the T wave morphology, its amplitude ( if low) and when it 
merges with a U or P wave. Various methods used to measure are: 
1. Threshold method.  
2. Slope method.  
3. Tangent method. 
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              Below in the first two figures,“to the original T wave (TH) or to its 
differential (DTH) the threshold method has been applied. In the slope method, a 
tangential line is drawn to the steepest point (SI) of descending arm of T wave. In the 
tangent method a line is drawn through (peak of) T wave and the maximum slope point 
(PSI).” 36 
              For exact measurement of QTd, we have to simultaneously record all the 12 
ECG leads so that there is no effect of heart rate on dynamicity of QT and it is 
considered the gold standard. The corrected QT dispersion has been used in many 
large scale studies. Additive & multiplicative formulae are used for heart rate 
correction. Although there is evidence for influence of rate, rhythm and site of 
impulse origin on ventricular recovery times it doesn‟t hold good for QT 
dispersion.
36 
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              But ultimately it depends on the shape of descending limb of T wave and 
its amplitude.
36 
Both T waves have the same offset (2
nd
 dashed vertical line) but 
descending waves are of different shapes. So in the first T wave there is 
underestimation and in second there is overestimation as per “teach the  tangent 
method” 
              In a study done by A.Cindas et al, QT dispersion was calculated in 
rheumatoid arthritis patients. “It was found that RA patients had more of diastolic 
dysfunction and heterogeneity of repolarization. Patients with disease duration of 
more than 5 years had significant longer values of QTd.”37 
              In another study, done in 38 patients with systemic sclerosis by Sgreccia.A 
et al, QTc interval and QT dispersion was significantly prolonged in systemic 
sclerosis patients when compared with controls.
38 
                 
Özhan Göldeli et al assessed QT and JT dispersion in patients with Behcet‟s 
disease and it was found to be increased significantly indicating regional variation in 
repolarization and the possible reason for ventricular arrhythmias.
39
    
            In an Iranian study done by Javad Kojuri et al, 124 SLE patients were 
studied. Two groups were formed, one with high disease activity (SLEDAI>10) and 
another with low disease activity (SLEDAI<10). QT dispersion was studied in them 
and it was found to have a significant correlation in the group with high disease 
activity. In patients with active disease, to assess the cardiac risk it can be used 
noninvasively as a simple tool.
2 
Assessment of disease activity:  SLE is an autoimmune disease involving multiple 
systems and is heterogenous in nature. Since the disease activity fluctuates widely it 
16 
 
is not possible to assess disease activity with a single tool.
40
 The five domains
41
 with 
which a patient with SLE is assessed are: 
 Disease activity 
 Damage  
 HAQoL  
 Adverse events 
 Economic costs & impact  
 In this study and also in our routine clinical practice, we use tools to assess disease 
activity which is an ongoing continuous process and is reversible. But disease 
damage is a permanent sequelae due to disease and is not reversible. In terms of 
disease activity usually three patterns are observed.
40-42
 They are: 
 Disease flare 
 Chronically active disease 
 Quiescence  
We have various modalities to assess disease activity like clinical assessment and 
laboratory investigations (hematology, urine examination, immunological tests etc.). 
All these will be incorporated into the various disease activity assessment indices. 
Two types of disease activity measurement indices are there: 
Global disease activity indices (overall burden of disease):  The disease 
activity and its recent changes are assessed. Disease activity can be quantified 
and is of immense use in clinical practice. No consideration is given for 
individual organs. Disease with multiple minor manifestations scores the 
same as few major organ manifestations . Many of the indices don‟t 
17 
 
differentiate the change in activity (improvement or worsening) over the past 
month.
43
 
Organ specific indices (activity in individual organ systems): Ideal tool for 
disease activity assessment in a heterogenous disease like SLE.  
The five commonly used disease activity assessment tools are:  
1. British Lupus Isles Assessment Group Index (BILAG) 
2. Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)  
3. Systemic Lupus Activity Measure (SLAM) 
4. The Lupus Activity Index (LAI) 
5. The European Consensus Lupus Activity Measurement Index (ECLAM) 
BILAG: 
It was first published in 1988. The index was initially based on eight organ systems, 
with manifestations occurring in the past 28 days.”Intent to treat” is the principle on 
which it is based. The ratings used are: 
Action (9): severe disease which needs a steroid dosage of – prednisone > 20mg/day 
+ other immunosuppressant‟s or anticoagulants ,added if necessary  
Beware (3): disease is less active and needs low dose steroids, antimalarials, 
NSAID‟S 
Contentment (1): disease is mild and stable, needs no modification of therapy 
Discount (0): system not affected now but affected in past  
E (0): system has never been affected 
18 
 
It is scored from 0 – 4 with 4 = new or recurrent; 3 = worsening; 2 = same; 1 = 
improving; 0 = absent. The systems included are general features, mucocutaneous, 
musculoskeletal, neurological, cardio respiratory, renal, haematological, ophthalmic, 
gastrointestinal and hepatic. 
Later the index was modified in 2004. In the new index the number of organ systems 
were increased to nine with inclusion of ophthalmologic, gastrointestinal & hepatic 
manifestations. The vasculitis category was taken off and its components were 
redistributed into the respective organ systems. Also some components like 
avascular necrosis were removed as it was more indicative of damage. Another 
important aspect is, there was no place for immunologic abnormalities in this 
system. To automatically calculate the A-E scores a computerised program called 
BLIPS (British Lupus Integrated Prospective System) is available. Even though it 
was initially studied in adult lupus it was also validated for childhood lupus in 
2004.
41-44 
SLEDAI: 
In 1985 there was introduction of SLEDAI, a global disease activi ty index. It is more 
objective, more convenient and commonly used in clinical practice. It has 24 
parameters based on nine organ systems and has a total score of 105 and the 
manifestations should be present in the previous ten days.
45,46
 It includes 
immunologic parameters and is more reliable and valid in both adult and childhood 
lupus. It also predicts the 6 month mortality rate (as mentioned in the table below).
47 
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 SLEDAI  RELATIVE RISK 
1-5 1.28 
6-10 2.34 
11-19 4.74 
>20 14.11 
 
Modifications of SLEDAI: 
MEX – SLEDAI :  
This was the MEXICAN version where the immunologic parameters were removed 
due to increased cost involved in calculating.
48
New features like mononeuritis 
multiplex, myelitis, fatigue were included with grouping of peritonitis with serositis, 
elevated creatinine with renal system, lymphopenia and hemolysis with 
haematological system. Features like pyuria, lupus headache and visual disturbances 
were omitted. The number of variables were decreased to ten and total score to only 
32. It was originally validated in only Spanish speaking countries and not widely 
used in trials.
48 
SELENA-SLEDAI:  
In the Safety of Estrogen in Lupus Erythematosus National Assessment Trial 
(SELENA) the SLEDAI was again modified. To improve the clarity, some of the 
definitions were modified. Seizures secondary to previous CNS damage and CVA 
secondary to hypertensive causes were excluded. New features like scleritis, 
episcleritis and vertigo were added. Proteinuria was modified by adding “new onset 
or recent increase in proteinuria to the existing definition of proteinuria more than 
500mg/day”.49 
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SLEDAI – 2K: 
 In 2002 it was introduced and also validated. The change here was , certain 
parameters like oral ulcers, rashes, alopecia and proteinuria were included by their 
mere presence and not necessarily new or recurrent ones. Like SLEDAI it is also a 
predictor of mortality. Then came the 30 day version of SLEDAI 2K. Like many 
other indices here also disease activity was assessed over the past 30 days. The 
explanation for the change was that, any manifestation present from 11
th
 to 30
th
 day 
can‟t resolve completely in the 10 days before a clinical visit. 50 
SLAM :  
It is another index which assesses the global disease activity and was introduced in 
1989. It has 31 items (23 clinical + 7 laboratory) encompassing 11 systems with a 
score of 86. The score ranges from 0-3. Later SLAM was revised with omission of 
immunologic parameters. Compared to other indices, subjective items are more in 
SLAM and hence patient‟s assessment is captured better.51 
ECLAM: 
In 1992 it was first introduced with a total of 15 manifestations (9 clinical + 3 
laboratory) with individual scores from 0.5-2 and a total score of only 10. Again the 
manifestatios present over previous 30 days are taken for assessment. It is best 
suited for retrospective studies and also validated for childhood lupus. But it is not 
often used in clinical trials.
52 
LAI :  It is divided into 5 parts  with scoring from 0-3 and the  manifestations 
scored, have to occur in the past 14 days.
46
 They are : 
- PGA : Physician‟s global assessment  
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- Arthritis, serositis, rash, fatigue 
- Renal , neurological, pulmonary and haematological  
- Steroids  and cytotoxic agents in high doses 
- Urinary sediments, anti ds DNA, C3, C4 levels 
Scoring is by calculating mean of part one score added to mean of 4 items of part 
two plus maximum score of part three plus mean of score in part four and five.  
             Lupus Foundation of America (LFA) formed a working group to define 
disease flare in lupus. They defined disease flare as “any increase in disease activity 
which can be measured and occurrence of a new manifestation or worsening of a 
manifestation in any organ system. It is a temporary measure which has to be 
considered clinically significant by the examiner and necessitating a change in 
treatment.”44 
             Disease activity is due to signs, symptoms or laboratory abnormalities 
present at the time of evaluation without any reference to  previous activity and flare 
is with reference to previous activity.
44 
Based on various indices flare can be defined. They are : 
1.SLEDAI: Increase by 3 – Flare 
                   Decrease by 3 – Improvement 
                   Within 3 Points – Persistent Disease 
                   Score of 0 - Remission  
2.BILAG: 
New category A – Severe Flare 
22 
 
Two, new category B manifestations – Moderate flare 53 
3. SELENA SLEDAI FLARE INDEX (SFI):
54,55 
It has 3 components.  
Mild flare is defined as: 
     a. SELENA SLEDAI score  >3 
     b. New or worsening disease activity (Fever, Arthritis, Serositis, Mucocutaneous   
lesions), change in medications (predisone <0.5 mg/kg/day) and addition of 
HCQ/NSAID‟s 
      c. Physician‟s global assessment (VAS: increase by 1.0-2.5) 
Severe flare is defined as: 
a. SELENA SLEDAI score > 12 
b. New or worsening of neuropsychiatric SLE, lupus nephritis, vasculitis, 
myositis.  
Platelet counts<60 000, hemolytic anemia with Hb<7% or decrease in Hb by        
3% 
Doubling of dosage of steroids / prednisolone>0.5 mg/kg/day or need for 
hospitalization 
Addition of cyclophosphamide, azathioprine, methotrexate etc.  
c. Increase in PGA > 2.5 
Improvement is assessed by: 
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RIFLE (Responder Index For Lupus Eryhtematosus): It is used in clinical trials 
to measure complete and partial responses. It can assess the change in disease 
activity over time. The response obtained is absent, complete resolution, incomplete 
response, unchanged or worsening of manifestations. It needs further validation and 
is not approved in childhood SLE.
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SLE Responder Index: It was first developed and used in a class II trial of 
Belimumab in SLE. Modified SLEDAI, SELENA-SLEDAI, BILAG and PGA have 
been incorporated in it to detect a change in disease activity. SELENA-SLEDAI was 
used to assess global disease activity, BILAG for individual systems and PGA was 
used so that importance is given also for patient‟s individual assessment. 57 
SLEDAI 2K Responder Index 50(SRI-50): 
It covers the same 9 systems and 24 variables present in SLEDAI 2K and score 
ranges from 0-105. To recognize a clinically meaningful improvement the clinician 
should document at least a 50% improvement in an individual variable.
58 
Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI): 
SLE has a wide variety of skin lesions categorized into acute, sub acute and chronic. 
But among the various manifestations, cutaneous lesions have never been studied 
systematically. The main reason is lack of a validated disease activity index to 
assess the effect of treatment. For developing a good cutaneous disease assessment 
index in SLE many had tried but very few exist. Few of them like Dermatology 
Index of Disease Severity (DIDS) exists but are quite rough, in their estimation of 
body surface area for diseases like SLE.
59
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Separate scores for activity and damage:  As present in other disease assessment 
scores of SLE, for skin also separate scores for activity and damage was proposed. 
The rationale is, a patient with scarring will have a stable score but clinically has no 
disease activity and only damage. The treatment for a scarred lesion is totally 
different from one with active disease but with the same score.
59
 It is scored 
separately for  
 1. Cutaneous lesions 
 2. Mucous membrane and 
 3. Alopecia 
For cutaneous involvement both activity and damage are scored. Areas scored are 
Scalp, Ears, Nose + Malar area, Rest of face, V area of neck, Posterior neck , Chest, 
Abdomen, Back + Buttocks , Arms, Hands, Legs and Feet – 13 areas in total. 
For cutaneous activity two aspects are scored: 
1. Erythema (score of 0-3) 
2. Scale / Hypertrophy (score of 0-2) 
For damage two aspects are scored: 
1. Dyspigmentation (score of 0-1) 
2. Scarring/Atrophy/Panniculitis(score of 0-2) 
For mucous lesions active lesions or ulcerations indicate activity and 
dyspigmentation indicates damage. 
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For alopecia scalp is divided into four quadrants with nonscarring alopecia 
indicating activity and scarring alopecia indicating damage.  
So the combined total score for cutaneous, mucous membranes and alopecia is 
scored separately for activity and damage. 
It has a total score of 70 and three grades of severity: 
60 
1. Mild disease  :  0-9 
2. Moderate disease  :  10-20 
3. Severe disease  :   21-70 
There is a separate scoring for associated symptoms like pain, itching and fatigue on 
a visual analog scale of 0-10. It was also found to have good content and face 
validity and also performed well for inter rater and intra rater validity. The extent of 
disease is assessed here by number of anatomical areas (those which are exposed 
given more importance than those which are covered by clothes) involved rather 
than the percentage of surface area involved, which have been used in other 
scores(eg. PASI). Erythema is the main parameter on which activity score is based 
and it is easy to recognize erythema even in dark skinned individuals. The average 
time required for scoring is five minutes
59 
In a study done by Salphale P et al. the CLASI score was applied to 93 patients of 
SLE with cutaneous lesions. The mean CLASI activity score was 15.4 and mean 
damage score was 6.87. Patients who had a combination of lesions had higher 
activity scores and damage scores positively correlated with the disease duration. 
Thus the effectiveness of CLASI for cutaneous disease assessment was shown in this 
study.
61 
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CLASI was not validated initially in studies conducted by rheumatologist s for 
disease activity and damage assessment. Jolly. M et al did a study on a group of 31 
patients with cutaneous SLE and used CLASI to assess the cutaneous activity and 
damage and found that it correlated well with the physician disease assessment for 
both activity and damage.
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A study done by Yokogawa N et al. conducted a trial on use of HCQ in cutaneous 
lupus and found that CLASI was a reliable tool to assess the treatment response to 
HCQ.
63
 
 In another study done by Bein.et al CLASI was used to assess the various types of 
skin lesions in cutaneous lupus. They found that i t is quite useful to assess overall 
disease activity and damage but not quite accurate to assess some of the individual 
subtypes and hence recommended a revision.
64 
Erythrocyte sedimentation rate: 
ESR is one of the oldest markers for inflammation still being used widely as it is 
cheap and easily done. Unlike other acute phase reactants  (whose concentration 
increases or decreases by more than 25% from baseline), it is an indirect measure of 
acute phase response. The change actually taking place is an increase in serum 
fibrinogen level plus other factors which influence ESR. ESR is the rate at which 
RBCs settle down when blood is kept in a vertical tube.  The surface charge and 
frictional forces of RBCs play a major role in determining the rate of erythrocyte 
sedimentation. To increase the rate of settling, the negative charge on RBCs (zeta 
potential) has to be decreased. The decrease in zeta potential is brought by an 
increase in asymmetrical proteins like fibrinogen and to some extent by alpha2, beta 
and gamma globulins. Other than these factors, even alteration in properties of RBCs 
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can influence ESR. Decrease in albumin or increase in cholesterol may increase 
ESR. Certain non inflammatory conditions (pregnancy, diabetes), malignancies, 
infections, chronic renal failure, monoclonal gammopathy and even drugs can 
influence ESR.
65-69 
As per the International committee for standardization in Hematology the 
recommended method for ESR estimation is Westegren method. The recommended 
upper limit value for males is 15mm/hr and for females is 20mm/hr. It also varies 
with age, race and sex.
68,69
 One of the formulas used for ESR estimation in males 
and females are : 
MALES = AGE/2                                                            
FEMALES = AGE+10/2 
G. Stojan et al found that disease activity as measured by SELENA-SLEDAI had significant 
correlation with ESR. It also correlated well with renal, haematological, arthritis, serositis, 
rash and Physician‟s global assessment (PGA).69 
In a survey of 570 SLE patients 56% of the patients had elevated ESR.
70 
Since it 
correlates well with disease activity it has found a place in the Systemic Lupus 
Activity Measure (SLAM).
71
 But the utility of ESR in monitoring disease activity is 
not certain as the studies available have been not consistent due to confounding 
factors and other coexisting conditions.
69 
As per the LUMINA study “553 SLE patients were studied in a total of 2317 visits.  
ESR was divided into four categories: normal (0-25mm/hr), mild (25-50mm/hr), 
moderate (50-75mm/hr) and severe increase (>75mm/hr). It was shown that mild, 
moderate and severe elevation in ESR had a strong correlation with disease activity 
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in SLE. Moderate and severe elevation also correlated better with extent of damage. 
Hence it was concluded that ESR is an easier and cheaper way of assessing disease 
activity and damage.
72 
But the limitation of the study was that the coexisting 
conditions were not studied properly.”  
In an Iranian study done by Nasiri et al, 100 patients with SLE were studied and 
found a significant association between BILAG scores and ESR.
73
On the contrary, in 
another study done by Mirzayan et al there was no correlation between ESR and disease 
activity. Similarly Chang et al showed no association between ESR and SLAM-R/SLEDAI. 
But patients with low ESR felt that their condition improved.”74 
In a study of HLA DR4 by T cells by Viallard et al 60 patients with SLE were studied and 
divided into high and low disease activity groups. They found that the high disease activity 
group had a quite high ESR.
75
 
In another study done by Samsonov MY et al. where ECLAM was being compared with 
neopterin, beta2 microglobulin, p55 TNF receptor, soluble IL 2 receptor and soluble CD8 
they found that ESR had a strong correlation with ECLAM.
76 
In a Brazilian study where the 
association between disease activity and terminal complement complex (sC5b-9) was studied 
it was found that ESR was raised in those with moderate and severe disease activity.
77 
URIC ACID AND SLE: 
In our study we found that many of our SLE patients had elevated serum uric acid. 
On searching the literature there was no study correlating the disease activity and 
levels of serum uric acid in SLE. Hence in our study we wanted to study the same.  In 
one of the German studies uric acid levels was assessed in patients with various 
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rheumatic disorders. A total of 1715 patients were studied and 79 of them had SLE. 
They found that average serum uric acid levels were higher in patients with SLE.
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In another study done by Frocht A et al 38 patients with SLE were studied. 29% of 
them had increased uric acid levels. It was found to have an association with renal 
involvement and in particular diuretic therapy and proteinuria. They also concluded 
that when uric acid levels are high with joint symptoms, gout has to be thought of  
rather than SLE arthritis, as symptoms due to gout may be suppressed by anti 
inflammatory medications.
79 
In a study done by Ho HH.et al 15 SLE patients were studied and two of them had 
overlap features. All these patients were under excretors and 14 of them were on 
diuretics. Many of them also had comorbidities like hypertension and cardiovascular 
problems. It was also found that gouty attacks occurred when SLE was inactive.
80 
Yang Z et al did a study to find an association between serum uric acid and lupus 
nephritis in patients with SLE. 130 SLE patients were studied and 73 of them had 
lupus nephritis. It was found that for development of lupus nephritis , uric acid was 
an independent risk factor. They also found a negative correlation between uric acid 
and complement(C3) levels in patients with lupus nephritis.
81 
In another study done by Kim KJ et al, 114 patients with SLE were studied and 7.9% 
of them had pulmonary hypertension and these patients also had high disease 
activity. It was found that serum uric acid levels were significantly elevated in 
patients with pulmonary hypertension and at levels more than 6.5 mg/dl it was 
predictive for the same with reasonable accuracy. It also correlated with pulmonary 
artery systolic pressure and NT-pro BNP levels. It was concluded that uric acid 
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levels can act as a surrogate marker for predicting development of pulmonary 
hypertension in SLE.
82 
In another study by Yang Z et al 191 SLE patients were studied and association 
between serum urea, creatinine and uric acid levels and clinical and laboratory 
parameters independent of renal involvement were studied. Serum uric acid level 
had a positive association with erythrocytopenia.
83 
In a study done by JM Sabio et al, a group of 102 SLE patients without obvious 
cardiovascular diseases secondary to atherosclerosis were studied. The main aim was to find 
any correlation between serum uric acid levels and arterial stiffness and inflammation 
markers. “They observed that patients with increased uric acid levels had a poor 
cardiovascular risk profile (inclusive of ageing, obesity, hypertension, raised cholesterol 
levels, metabolic syndrome and renal disease). They also found that SLE duration was more 
with increased accrual of damage. It was concluded that in SLE patients without obvious 
atherosclerotic cardiovascular disease, uric acid levels may be an ancillary indicator of 
subclinical atherosclerosis.”84 
Anti Ro and Anti La antibodies: 
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A group of cytoplasmic ribonucleoproteins containing the 60-kDa Ro antigen and 
one of the Y1, Y3, Y4 or Y5 RNA molecules are recognized by Anti Ro 
autoantibodies. A donut like structure is formed by Ro 60 antigen through which 
ssRNA passes. The 47-kDa La antigen is transiently associated with precursors of 
many small RNAs being synthesized by RNA polymerase III and to protect them 
from the activity of exonucleases. Hence for RNA polymerase III, the termination 
factor is La antigen. Ro 60 also attaches to RNAs which are misfolded and helps in 
quality control of U2 and 5S ribosomal RNA. UV radiation promotes misfolding of 
RNA and anti Ro confers protection by promoting degradation of the same. Though 
Ro 52 is not an integral part of Y1-Y5 RNP particles, anti Ro 52 antibodies usually 
coexist with anti Ro 6o and La auto antibodies.  
The diseases with which anti Ro and La auto antibodies  associated  are  Sjogren‟s 
syndrome, SLE, PM/DM and SSc. The prevalence rates of anti Ro 60 autoantibodies 
are 60-80% in primary Sjogren‟s syndrome and 10-50% in SLE. The anti La 
antibodies have a prevalence of 10-20% in both Sjogren‟s and SLE and it always 
coexists with anti Ro 60 and/or La. All three antibodies also predispose to neonatal 
cardiac abnormalities like congenital complete heart block.  Pregnant patients with 
previous history of conduction defects in fetus or patients with SLE should be 
screened for the presence of these auto antibodies as it increases the fetal risk during 
pregnancy. Usually it is the IgG antibodies which crosses the placenta and binds  the 
autoantigens present on apoptotic cells. The inflammatory response and fibrosis with 
production of TNF is mediated by Fc receptors. The second trimester (particularly 
22
nd
 - 30
th
 weeks) is the period with increased risk and needs fetal cardiac 
monitoring. Dexamethasone or plasmapheresis has a role in treatment of low grade 
heart block.
85-88
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The manifestations associated with anti Ro in SLE patients are photosensitivity, 
cutaneous lupus, chilblains, sicca symptoms, congenital heart block, anti La, 
Rheumatoid factor, C4 deficiency, pulmonary disease, endocardial fibroelastosis, 
lymphopenia and thrombocytopenia. Anti La is associated with late onset SLE, 
secondary Sjogren‟s and also protection from nephritis due to anti Ro. 89-91 
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Materials and methodology 
The study was done on newly detected SLE patients admitted in the Department of 
Rheumatology, Madras Medical College & RGGGH, Chennai . 
Duration of study: January 2012 – December 2013 
Design of the study: Prospective analytical study 
Ethical committee approval: Obtained before starting the study. 
Consent: Informed consent in patients own language was obtained 
Study group: 100 consecutive SLE patients and 100 age matched controls attending 
the Department of Rheumatology, RGGGH, Chennai who satisfied the inclusion 
criteria were studied. 
Inclusion Criteria: 
-  Patients who satisfied the 1997 revised ACR classification criteria for SLE 
with a normal good quality resting ECG were included in the study group. 
- Patients who attended master health check up and other outpatients who had 
non rheumatological disorders. 
Exclusion Criteria:  
- Patients with electrolyte disturbances.  
- Drugs prolonging QT interval (except chloroquine). 
    -    Patients with baseline ECG abnormalities (eg: bundle branch blocks , presence 
of U waves). 
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    -      Pre-existing cardiac disease (eg: ischemic heart disease, congestive heart 
failure, rhythm abnormalities) 
   -      Renal failure 
Methodology: 
All patients who satisfied the inclusion criteria were chosen and detailed history was 
obtained and complete clinical examination was done. Patients were subjected to 
baseline blood investigations and immunological investigations. ESR was calculated 
with Westergren‟s method & serum uric acid (determined by Trinder‟s method) with 
automated analyser. ANA was done by either ELISA or IIF by Hep-2 method, anti 
dsDNA by ELISA & complements by nephelometry. ANA profile 3 was done by 
EUROIMMUNE Line Immunoassay (Immunoblot). 
              A standard 12 lead Electrocardiogram was obtained with a speed of 
25mm/sec & 10mm/mV amplitude. QT interval was calculated from beginning of „q‟ 
wave to end of T wave in lead II or lateral leads (V5,V6). QT dispersion was 
measured as the difference between maximum & minimum QT intervals. Trans 
thoracic Echocardiogram was done by a cardiologist.  
         Patient‟s generalized disease activity was calculated with SLEDAI (Annexure 
A2) and CLASI (Annexure A3) was used to assess the activity and damage due to 
skin lesions. The same disease activity measurement tools were used during each 
flare on follow up and necessary blood investigations (baseline & immunological), 
urine routine and repeat ECG were also obtained.  
 QT interval calculation: In the diagram below we can see two consecutive cardiac 
cycles with measurement of QT interval from where QRS starts to where T wave 
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ends. The typical U wave is also seen but it should be excluded from the calculation. 
Then the interval between two cardiac cycles (i.e RR interval) should be calculated. 
Then the Bazett‟s formula was used to calculate the corrected QT interval.  
 
 
Statistical analysis: 
For discrete data proportion are computed and the mean and standard deviation are 
computed for the continuous data. The Chi square test was applied to compare the 
proportions between the groups. The independent t test was used to compare the 
mean between the groups. All analyses were two tailed and p<0.05 was considered 
significant. Pearson‟s correlation coefficient was used to measure the linear 
correlation between two variables. SPSS version 21.0 was used for data analysis.                                   
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ANA ELISA 
Principle: 
In the ANA screen ELISA kit, purified nuclear antigens are being coated on to  wells 
of microtitre plate. If IgG type of ANA specific antibody is present it binds to the 
antigen. Washing is done to remove all the unbound materials. If any antigen 
antibody complex is there, it binds to the added enzyme conjugate. Again washing is 
done to remove excess enzyme conjugate and then substrate is  added. On incubation 
of the plate there is hydrolysis of the substrate by the enzyme.   
Test procedure: 
 Universal precautions are followed during the procedure. All the 
reagents are dispensed in the centre of the well and the tip of the 
pipette should not touch the wall of the micro well.  
 Prepare work sheet and remove the kit from the refrigerator and leave 
it at room temperature for 30 minutes.  
Sample: 
 Use only serum as specimen for the test  
Preparation of wash buffer: 
 Check the buffer concentrates for the presence of salt crystsls.  
          50ml of buffer is prepared for each strip 
 Mix 20ml 25x wash buffer concentrate with 480 ml of distilled water  
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Procedure: 
 Samples to be brought to room temperature 
 Samples arranged so that well A1 is negative control and well B1 is 
positive control and well C1 & D1 is calibrator.  
 To 200 µl of sample diluents, 10 µl of test sample is added to make a 
1:21 dilution and mixed nicely. 
 Dispense 100 V of diluted sera in E1 well & other diluted samples in 
their appropriate wells. Tap the holder to remove air bubbles from the 
liquid and mix well gently and cover with a seal.  
 At room temperature incubation  is done for 20 minutes   
 The seal is removed and wash buffer of 300 µl is used to wash the 
wells thrice.  
 An absorbent paper is used for blotting.  
 In each well enzyme conjugate of 100 µl is added.  
 The plate is sealed with a cover and is incubated for 20 minutes at 
room temperature. 
 The seal is removed and wash buffer of 300 µl is used to wash the 
wells thrice.  
 An absorbent paper is used for blotting.  
 Dispense 100 µl of TMB substrate and incubate for 10 minutes at room 
temperature. 
 Add 100 µl of stop solution. 
 Read at 450 nm using ELISA reader 
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 ANA – INDIRECT IMMUNOFLUORESCENCE (Hep-2)
  
Principle: 
The antibodies present in the sample bind the relevant antigens. Once bound, the 
antigen-antibody complex is shown with an antibody conjugated with fluorescein 
and is visualized under a fluorescent microscope. 
Test procedure: 
 Keep the slides at room temperature for 30 minutes before performing 
the assay. 
 The phosphate buffer saline is prepared before performing the assay.  
 According to the slide to be used, prepare a screening dilution.  
Reagents 1/10 dilution 1/40 dilution 
PBS  buffer 450 µl 300 µl 
Serum 50 µl 100 µl 
 With diluted samples and diluted controls the reactive areas are 
covered. 
 Incubation is done at room temperature for a period of 30 minutes. 
Perform a quick wash with PBS. 
 Three washings should be performed of 5 minutes each, putting the 
slides in the coplin jar containing PBS, shaking softly. 
 Take the slides off the PBS, shake the excess on absorbent paper and 
keep the reactive areas wet. 
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 Diluted Anti IgG FITC is used to cover the reactive areas immediately 
and kept for incubation at room temperature in a moist chamber for 30 
minutes. 
 Steps for washing to be repeated. 
 Cover the reactive areas with Evan‟s blue.  
 Wash the excess stain with PBS, keeping the reactive areas wet.  
 Put the mounting medium immediately on the cover slide.  
 Results are interpreted based on the pattern and the intensity of 
fluorescence in 1/40 dilution. Positive reaction in 1/10 dilution but 
negative in 1/40 dilution is reported as negative.  
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ANA profile 3 
Procedure: 
 
To take the strip provided by the manufacturer and place it on the tray.  
 
To add 10 µl serum sample to 100 µl diluents (30 minutes Incubation) 
 
Thrice washed with 1.5 ml wash buffer (incubate for 5min / wash) 
 
Add 100 µl conjugate (30 minutes Incubation) 
 
Thrice washed with 1.5 ml wash buffer (incubate for 5 min / wash) 
 
Add 100 µl substrate (10 minutes Incubation) 
 
Wash with 1.5 ml distilled water 
 
Add 100 µl stop solution (5 minutes Incubation)  
 
 Read results   
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Results and Analysis 
Table 1: Age wise distribution of study cases 
Age (years) Males Females Total 
17- 20 2 22 24 
21-25 6 31 37 
26-30 5 17 22 
31-35 1 7 8 
36-40 - 5 5 
41-45 - 2 2 
46-50 - 1 1 
51-55 - 1 1 
 
 
                                            Figure 1 Age Distribution 
The study group had 59% of the patients (48% - females & 11% - males) in the age 
group of 21-30 years. There were 24% (22% - females & 2% males) of patients in 
age group of 17-20 years. The maximum number of patients were from 2
nd
 and 3
rd
 
decades. 
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Figure 2 : Gender Distribution 
 
           Table 2: Sex distribution in cases and controls  
 Males Females Total 
Cases 14 86 100 
Controls 25 75 100 
 
Among the cases 86% were females and 14% were males. Among the controls 75% 
were females and 25% were males. 
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                     Table 3: Clinical features 
Type of manifestation No: of subjects (%)  (n=100) 
Fever 81 
Arthritis 61 
Cutaneous 58 
Neuropsychiatry 45 
Renal 44 
Hematological 43 
Myositis 41 
Hepatomegaly/Splenomegaly 39 
Lymphadenopathy 33 
Serositis 32 
Cardiovascular 29 
Pulmonary 11 
Weight loss 11 
 
 
Figure 3 Clinical Features 
In our study group 61% had arthritis ,58% had cutaneous,45% had neuropsychiatry, 
44% had renal involvement, 43% had serositis, 32% had haematological , 29% had 
CVS involvement and  41% had myositis.  
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Table 4: Lupus nephritis (ISRN/RPS 2003)  
              
Class No: patients % 
I 2 4.54 
II 3 6.81 
III 10 22.72 
IV 17 38.63 
V 7 15.9 
VI 1 2.27 
III + V 1 2.27 
IV + V 2 4.54 
V + VI 1 2.27 
 
 
Figure 4 Lupus nephritis 
 
In our study group class IV lupus nephritis was common (38.63%), followed by class 
III (22.72%) and class V (15.9%). 
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Table 5: Frequency of Auto antibodies 
Auto antibodies No. of Patients (%) 
anti Sm 49 
anti Ro 47 
anti ds DNA 45 
anti U1 RNP 42 
anti Histone 31 
anti Ribosomal P protein  28 
anti Nucleosome  28 
anti La 10 
 
 
Figure 5 - Auto antibodies (%) 
Anti Sm was found in 49%, followed by Anti Ro (47%), Anti ds DNA (45%) and 
Anti U1RNP(42%). 
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Table 6: SLEDAI distribution 
 Frequency Percent Valid Percent Cumulative 
Percent 
 Valid 
UP TO 5 1 1.0 1.0 1.0 
6-10 15 15.0 15.0 16.0 
11-15 21 21.0 21.0 37.0 
16-20 17 17.0 17.0 54.0 
21-25 22 22.0 22.0 76.0 
26-30 9 9.0 9.0 85.0 
31-35 6 6.0 6.0 91.0 
36-40 5 5.0 5.0 96.0 
41-45 4 4.0 4.0 100.0 
Total 100 100.0 100.0  
 
 
 
 
Figure 6 SLEDAI 
84% of the patients in our study had high disease activity.  
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Table 7: Disease Flare 
 Frequency Percent Valid Percent Cumulative 
Percent 
 
 
75 75.0 75.0 75.0 
mild 7 7.0 7.0 82.0 
moderate 9 9.0 9.0 91.0 
severe 9 9.0 9.0 100.0 
Total 100 100.0 100.0  
 
 
 
 
 
Figure 7 patients with flare 
In our study group of 100 patients, 25 patients had flare, of which 28% had mild 
flare, 36% had moderate flare and 36% had severe flare.  
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Table 8: ESR* distribution 
 Frequency Percent Valid Percent Cumulative 
Percent 
Valid 
UP TO 25 
4 4.0 4.0 4.0 
26-50 41 41.0 41.0 45.0 
51-75 41 41.0 41.0 86.0 
76-100 14 14.0 14.0 100.0 
Total 100 100.0 100.0  
*correction for anemia : corrected Hb =  ( ESR X Hematocrit/45 ) 
 
 
Figure 8 - ESR distribution 
 
In our study group, 4% had ESR less than 25 mm/hr, 41% had between 26-50 mm/hr, 
41% between 51-75 mm/hr and 14% had ESR between 76-100 mm/hr. 
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Table 9a: Acute cutaneous lupus 
 Frequency Percent Valid Percent Cumulative Percent 
Valid 
NO 58 58.0 58.0 58.0 
YES 42 42.0 42.0 100.0 
Total 100 100.0 100.0  
 
Table 9b: Subacute cutaneous lupus  
 Frequency Percent Valid Percent Cumulative Percent 
Valid 
NO 74 74.0 74.0 74.0 
YES 26 26.0 26.0 100.0 
Total 100 100.0 100.0  
 
Table 9c: Chronic cutaneous lupus 
 Frequency Percent Valid Percent Cumulative Percent 
Valid 
NO 87 87.0 87.0 87.0 
YES 13 13.0 13.0 100.0 
Total 100 100.0 100.0  
 
 
Figure 9 - Cutaneous Lupus Types 
In our study group 42 had acute cutaneous lesions, 26 had sub acute cutaneous 
lesions and 13 had chronic cutaneous lesions.     
42 26 
13 
No.of patients with cutaneous lupus 
acute
sub acute
chronic
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To find if there is any difference in the mean QTc between cases and controls  
Group Statistics( t test) 
 GROUP N Mean Std. Deviation Std. Error Mean 
Corrected QT interval 
Cases 100 436.30 27.433 2.743 
Controls 100 397.24 31.853 3.185 
QT dispersion 
Cases 100 44.40 20.613 2.061 
Controls 100 39.20 17.734 1.773 
 
                                                                                          Independent Samples Test 
 Levene's Test for 
Equality of Variances 
t-test for Equality of Means 
F Sig. t df Sig. (2-
tailed) 
P value 
Mean 
Difference 
Std. Error 
Difference 
95% Confidence Interval 
of the Difference 
Lower Upper 
Corrected QT 
interval 
Equal variances 
assumed 
4.407 .037 9.292 198 .000 39.060 4.204 30.770 47.350 
Equal variances not 
assumed 
  9.292 193.74
0 
.000 39.060 4.204 30.769 47.351 
QT dispersion 
Equal variances 
assumed 
4.809 .029 1.912 198 .057 5.200 2.719 -.162 10.562 
Equal variances not 
assumed 
  1.912 193.68
3 
.057 5.200 2.719 -.163 10.563 
Inference: QTc difference between cases and controls is statistically significant as p<0.0001 and the QTd difference is not 
significant between the cases and controls.  
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To find out the correlation between baseline QTc interval and QTc interval during flare  
Variables: 
QTcb1=QTc value at the beginning for mild flare cases corresponding to QTcf1 value. 
QTcb2=QTc value at the beginning for moderate flare cases corresponding to QTcf2 value 
QTcb3=QTc value at the beginning for severe flare cases corresponding to QTcf3 value 
Test of relationship between QTc values for flare cases with baseline QTc values is seen by 
Pearson‟s correlation coefficient. 
 
Paired Samples Correlations  
 N Correlation Sig. 
Pair 1 QTcb1 & QTcf1 7 .433 .331 
Pair 2 QTdb1 & QTdf1 7 .559 .192 
Pair 3 QTcb2 & QTcf2 9 .560 .117 
Pair 4 QTdb2 & QTdf2 9 .280 .466 
Pair 5 QTcb3 & QTcf3 9 .863 .003 
Pair 6 QTdb3 & QTdf3 9 .614 .079 
Inference: 
QTc baseline and QTc during a flare have a positive correlation  and similarly QTd baseline and QTd during flare also have 
a positive correlation. 
But only the difference between severe (flare) associated QTc values and baseline QTc values are statistically significant.  
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To find out the difference between the mean QTc (baseline) and mean QTc (flare) 
and mean QTd (baseline) and mean QTd (flare). 
Paired Samples Test 
 Paired Differences t df Sig. (2-tailed) 
P value Mean Std. Deviation Std. Error Mean 95% Confidence Interval of the 
Difference 
Lower Upper 
Pair 1 QTcb1 - QTcf1 5.429 24.144 9.126 -16.901 27.758 .595 6 .574 
Pair 2 QTdb1 - QTdf1 20.000 25.820 9.759 -3.879 43.879 2.049 6 .086 
Pair 3 QTcb2 - QTcf2 -6.333 18.480 6.160 -20.538 7.871 -1.028 8 .334 
Pair 4 QTdb2 - QTdf2 .000 20.000 6.667 -15.373 15.373 .000 8 1.000 
Pair 5 QTcb3 - QTcf3 -6.667 8.456 2.819 -13.166 -.167 -2.365 8 .046 
Pair 6 QTdb3 - QTdf3 -4.444 16.667 5.556 -17.256 8.367 -.800 8 .447 
 
Inference: 
QTc difference for cases with severe flare is statistically significant.  
For cases with mild and moderate flare the difference is not significant for QTc as well for QTd.  
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Mean QTc interval and QTd of anti Ro (+ ve) vs anti Ro (- ve) patients 
Group Statistics  
 Anti Ro Antibody N Mean Std. Deviation Std. Error Mean 
Corrected QT interval(cases) 
Positive 47 448.87 17.926 2.615 
Negative 53 425.15 29.648 4.072 
QT dispersion (cases) 
Positive 47 44.26 20.825 3.038 
Negative 53 44.53 20.622 2.833 
 
Independent Samples Test 
 Levene's Test for Equality 
of Variances 
t-test for Equality of Means 
F Sig. t df Sig. (2-
tailed) 
P value 
Mean 
Difference 
Std. Error 
Difference 
95% Confidence Interval 
of the Difference 
Lower Upper 
Corrected QT 
interval(cases) 
Equal variances 
assumed 
15.057 .000 4.765 98 .000 23.721 4.978 13.843 33.600 
Equal variances not 
assumed 
  4.902 86.997 .000 23.721 4.840 14.102 33.341 
QT dispersion 
(cases) 
Equal variances 
assumed 
.014 .907 -.066 98 .948 -.273 4.151 -8.510 7.964 
Equal variances not 
assumed 
  -.066 96.341 .948 -.273 4.153 -8.517 7.971 
Inference: 
The mean QTc difference between anti Ro positive and anti Ro negative cases are statistically significant .  
The mean QTd difference is not significant for Anti Ro positive and negative cases.  
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Mean QTc interval and QTd of anti La (+ ve) vs anti La (- ve) patients   
                                                                                                      Group Statistics 
 Anti La Antibody N Mean Std. Deviation Std. Error Mean 
Corrected QT interval(cases) 
Positive 10 445.90 21.236 6.716 
Negative 90 435.23 27.929 2.944 
QT dispersion (cases) 
Positive 10 40.00 13.333 4.216 
Negative 90 44.89 21.266 2.242 
 
Independent Samples Test 
 Levene's Test for Equality 
of Variances 
t-test for Equality of Means 
F Sig. t df Sig. (2-
tailed) 
P value 
Mean 
Difference 
Std. Error 
Difference 
95% Confidence Interval 
of the Difference 
Lower Upper 
Corrected QT 
interval(cases) 
Equal variances 
assumed 
1.273 .262 1.169 98 .245 10.667 9.128 -7.447 28.780 
Equal variances not 
assumed 
  1.455 12.744 .170 10.667 7.333 -5.207 26.540 
QT dispersion (cases) 
Equal variances 
assumed 
6.849 .010 -.710 98 .480 -4.889 6.888 -18.558 8.781 
Equal variances not 
assumed 
  -1.024 14.688 .322 -4.889 4.775 -15.086 5.308 
Inference: 
The mean QTc difference and the mean QTd difference between anti La positive and negative cases are not statistically significant.  
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Table 10: CLASI activity and damage scores of Acute, 
Subacute and Chronic cutaneous lesions 
 
 
 
 No. of 
patients 
Mean Std.Deviation Std.Error 
Mean 
Acute 
CLASI 
activity 
42 8.88 7.235 1.116 
Acute 
CLASI 
damage 
42 3.00 4.596 .709 
Subacute 
CLASI 
activity 
26 13.54 8.296 1.627 
Subacute 
CLASI 
damage 
26 5.54 4.329 .849 
Chronic  
CLASI 
activity 
13 10.23 8.228 2.282 
Chronic  
CLASI 
damage 
13 8.23 5.805 1.610 
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Table 11: Correlation between SLEDAI and corrected QT 
interval (QTc) in cases 
 
Correlations 
 SLEDAI Corrected QT 
interval(cases) 
SLEDAI 
Pearson Correlation 1 .331
**
 
Sig. (2-tailed)  .001 
N 100 100 
Corrected QT interval(cases) 
Pearson Correlation .331
**
 1 
Sig. (2-tailed) .001  
N 100 100 
**. Correlation is significant at the 0.01 level (2-tailed). 
Inference: 
The Pearson Correlation coefficient „r‟=0.331 between the SLEDAI and QTc is 
statistically significant as p = .001. 
Hence we conclude that there is significant correlation between SLEDAI and QTc 
interval. 
  
 
Table 12:  Correlation between SLEDAI and QTdispersion 
(QTd) in cases 
 
Correlations 
 SLEDAI QT dispersion 
(cases) 
SLEDAI 
Pearson Correlation 1 -.048 
Sig. (2-tailed)  .632 
N 100 100 
QT dispersion (cases) 
Pearson Correlation -.048 1 
Sig. (2-tailed) .632  
N 100 100 
 
Inference: 
The Pearson Correlation coefficient „r‟=-0.048 between the SLEDAI and QTd is not 
statistically significant as p=0.632 >0.05 
Hence we conclude that there is no correlation between SLEDAI and QTd.  
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Table 13: To find out correlation between between the 
QTc(cases) and the CLASI  
Correlations 
 Corrected QT 
interval(cases) 
CLASI  
Corrected QT interval(cases) 
Pearson Correlation 1 .101 
Sig. (2-tailed)  .321 
N 100 99 
CLASI  
Pearson Correlation .101 1 
Sig. (2-tailed) .321  
N 99 99 
 
Inference: 
As „r‟=0.101 and p=0.321, the relationship between the QTc and CLASI is not 
established. 
 
 
Table 14: To find whether there is correlation between the 
QTd(cases) and the CLASI 
Correlations 
 QT dispersion 
(cases) 
CLASI  
QT dispersion (cases) 
Pearson Correlation 1 .106 
Sig. (2-tailed)  .294 
N 100 99 
CLASI  
Pearson Correlation .106 1 
Sig. (2-tailed) .294  
N 99 99 
 
 
Inference: 
As „r‟=0.106 and p=0.294, the relationship between the QTd and CLASI is not 
established. 
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Table 15: To find out correlation between the SLEDAI and 
the CLASI 
 
Correlations 
 SLEDAI CLASI  
SLEDAI 
Pearson Correlation 1 -.145 
Sig. (2-tailed)  .153 
N 100 99 
CLASI  
Pearson Correlation -.145 1 
Sig. (2-tailed) .153  
N 99 99 
 
Inference: 
As „r‟=-0.145 and p=0.153, the relationship between the SLEDAI and CLASI is not 
established. 
 
 
Table 16: To find out correlation between the SLEDAI and 
ESR 
 
Correlations  
 SLEDAI ESR 
SLEDAI 
Pearson Correlation 1 .329
**
 
Sig. (2-tailed)  .001 
N 100 100 
ESR 
Pearson Correlation .329
**
 1 
Sig. (2-tailed) .001  
N 100 100 
**. Correlation is significant at the 0.01 level (2 -tailed). 
 
Inference: 
As „r‟=-0.329 and p=0.001, the relationship between the SLEDAI and ESR is 
positive and statistically significant. 
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Table 17: To find out correlation between the SLEDAI and 
Serum Uric Acid 
 
Correlations  
 SLEDAI URIC ACID 
SLEDAI 
Pearson Correlation 1 .339
**
 
Sig. (2-tailed)  .001 
N 100 100 
URIC ACID 
Pearson Correlation .339
**
 1 
Sig. (2-tailed) .001  
N 100 100 
**. Correlation is significant at the 0.01 level (2 -tailed). 
 
Inference:  
As „r‟=-0.339 and p < 0.01, the relationship between the SLEDAI and serum 
uric acid is positive and statistically significant.  
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Table 18 a: Correlation between acute cutaneous lesions and 
CLASI activity index: 
Correlations 
 ACUTE 
CUTANEOUS 
CLASI Activity 
index 
ACUTE CUTANEOUS 
        (YES/NO) 
Pearson Correlation 1 .289
**
 
Sig. (2-tailed)  .004 
N 100 100 
CLASI Activity index 
Pearson Correlation .289
**
 1 
Sig. (2-tailed) .004  
N 100 100 
**. Correlation is significant at the 0.01 level (2 -tailed). 
 
 
Inference : 
As „r‟=-0.289 and p < 0.01, the relationship between acute cutaneous lesions and 
CLASI activity index is positive and statistically significant. 
 
Table 18 b: Correlation between acute cutaneous lesions and 
CLASI damage index: 
 
 ACUTE 
CUTANEOUS 
CLASI DAMAGE 
INDEX 
ACUTE CUTANEOUS 
        (YES/NO) 
Pearson Correlation 1 .083 
Sig. (2-tailed)  .413 
N 100 100 
CLASI DAMAGE INDEX 
Pearson Correlation .083 1 
Sig. (2-tailed) .413  
N 100 100 
 
 
As „r‟=-0.083 and p = 0.413, the relationship between acute cutaneous lesions and 
CLASI damage index is not statistically significant.  
Hence we conclude that the difference in the slope of the trends is insignificant.  
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                   a. Malar rash                       b. Malar rash with angioneurotic edema  
 
 
 
  
c. Malar rash with oral mucositis                d. Cutaneous vasculitis  
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Table 19 a : Correlation between subacute cutaneous lesions 
and CLASI activity index: 
Correlations 
 SCLE 
YES/NO 
CLASI Activity 
index 
SCLE YES/NO 
Pearson Correlation 1 .595
**
 
Sig. (2-tailed)  .000 
N 100 100 
CLASI Activity index 
Pearson Correlation .595
**
 1 
Sig. (2-tailed) .000  
N 100 100 
**. Correlation is significant at the 0.01 level (2 -tailed). 
 
 
Inference : 
As „r‟=-0.595 and p < 0.01, the relationship between subacute cutaneous lesions 
and CLASI activity index is positive and statistically significant . 
 
Table 19 b : Correlation between subacute cutaneous lesions 
and CLASI damage index: 
 
Correlations 
 SCLEY/N CLASI DAMAGE 
INDEX 
SCLEY/N 
Pearson Correlation 1 .415
**
 
Sig. (2-tailed)  .000 
N 100 100 
CLASI DAMAGE INDEX 
Pearson Correlation .415
**
 1 
Sig. (2-tailed) .000  
N 100 100 
**. Correlation is significant at the 0.01 level (2 -tailed). 
 
Inference : 
As „r‟=-0.415 and p < 0.01, the relationship between subacute cutaneous lesions 
and CLASI damage index is positive and statistically significant.  
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e.Subacute and discoid lesions 
 
 
f. discoid lesions over face and ears 
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Table 20 a : Correlation between chronic cutaneous lesions 
and CLASI activity index: 
 
Correlations 
 CHRONIC 
YES/NO 
CLASI Activity 
index 
CHRONIC YES/NO 
Pearson Correlation 1 .206
*
 
Sig. (2-tailed)  .040 
N 100 100 
CLASI Activity index 
Pearson Correlation .206
*
 1 
Sig. (2-tailed) .040  
N 100 100 
*. Correlation is significant at the 0.05 level (2 -tailed). 
 
Inference : 
As „r‟=-0.206 and p < 0.05, the relationship between chronic cutaneous lesions 
and CLASI activity index is positive and statistically significant.  
 
Table 20 b : Correlation between chronic cutaneous lesions 
and CLASI damage index: 
Correlations 
 CHRONIC 
YES/NO 
CLASI DAMAGE 
INDEX 
CHRONIC YES/NO 
Pearson Correlation 1 .517
**
 
Sig. (2-tailed)  .000 
N 100 100 
CLASI DAMAGE INDEX 
Pearson Correlation .517
**
 1 
Sig. (2-tailed) .000  
N 100 100 
**. Correlation is significant at the 0.01 level (2 -tailed). 
 
Inference : 
As „r‟=-0.517 and p < 0.01, the relationship between chronic cutaneous lesions 
and CLASI damage index is positive and statistically significant.  
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g. Discoid lesions over scalp                     h. Discoid lesions over palms 
 
 
 
     i.Discoid lesions over scalp                                j. Discoid lesions over back 
                                                                                   (Disseminated discoid) 
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Discussion 
              SLE is the typical autoimmune disease with fluctuating disease activity. 
The disease activity has to be controlled with treatment , for which one has to 
monitor disease activity. We have various measures like anti ds DNA and 
complements for assessing disease activity which places a significant financial strain 
on patients. Hence in this study we studied various parameters which can be used as 
surrogate markers for assessing disease activity during follow up of SLE patients.  
             In our study, 100 consecutive patients of SLE getting admitted  as in patients 
were included and their clinical profile, laboratory parameters including 
immunological investigations were studied. QT interval parameters were studied and 
compared with age and sex matched controls.  
             In our study we had 59% of the patients (48% - females & 11% - males) in 
the age group of 21-30 years and 24% (22% - females & 2% males) of patients in the 
age group of 17-20 years. The majority of patients were in their 2
nd
 and 3
rd
 decades 
with an average age of 25.45 years. The female to male ratio in our study was 6:1. In 
a study done by Renu Saigal et al. the female to male ratio was 11:1.
92
 In other 
Indian studies done by Binoy et al and Malaviya et al the female to male ratio were 
19:1 and 8:1.
93,94
The average disease duration in our study was 1.63 years and 2 
years in the study done by Renu Saigal et al and 17 months in the study done by 
Malaviya et al.
92,94
The mean age of onset of disease in our study was 25.45 years 
and the median age of onset in studies done by Renu Saigal et al and Binoy et al was 
27.9 and 21.6 years.
92,93
Other Indian studies done by Malaviya et al and Vaidya et al 
had a median age of onset of 24 and 26 years.  Hence in all Indian studies, the 
median age of onset was similar.
94,95 
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Clinical features Our study 
(n = 100) 
2014, 
S.India(Chennai) 
Malaviya et al 
(n = 101) 
1985, N.India 
Madhavan et 
al 
(n = 54) 
1983, Madras 
Binoy et al 
(n = 75) 
2003 
S.India, 
N.Kerala 
Vaidya et al 
(n = 220) 
1997 
W.India 
Renu Saigal et 
al 
(n = 60) 
2011 
W.India 
Fever 81% 44% 11.1% 4.0% NA 6.7% 
Lymphadenopathy 33% NA NA NA NA NA 
Hepatomegaly/ 
Splenomegaly 
39% NA NA NA NA NA 
Weight loss 11% NA NA NA NA NA 
Arthritis 61% 66% 81.4% 89.3% 70.91% 86.7% 
Myositis 41% NA NA NA NA NA 
Cutaneous 58% 85% 62.9% 64% NA NA 
Cardiovascular 29% 5% 9.2% 5.3% 11.8% 6.7% 
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Pulmonary 11% 17% 16.6% 8% 15.5% 11.7% 
Renal 44% 73% 38.8% 33.3% 35% 56.7% 
Neuropsychiatry 45% 15% 20.3% 13.3% 25.5% 13.3% 
Hemolytic anemia 29% NA NA 0.01% NA 25% 
Leukopenia 26% 16% 3.7% 14.7% NA 43.3% 
Thrombocytopenia 39% 11% 7.4% 12% NA 33.3% 
Serositis 32% NA NA NA NA NA 
Raynauds 7% 32% 1.8% 2.7% 15.5% 21.&% 
ANA 100% 98% NA 93.3% NA 98.3% 
ds DNA 45% 55% NA 76% NA 65% 
Complements 72% NA NA NA NA NA 
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QT interval parameters are important prognostic markers for assessing cardiac risk 
in SLE patients. In our study the mean QTc interval was 436.30 msec (S.D of 27.43) 
among cases and mean QTd among cases was 44.40msec (S.D 20.61).  
 Our study 
(2014) 
Cardoso et al
10 
(2005) 
  (Cases) 
 (n = 100) 
 
(Controls) 
2014(n = 100)  
 
(Cases)  
 (n = 140) 
 
(Controls)  
(n = 37) 
 
QTc mean 436.30 397.24 427.91 410.05 
QTc > 440 ms 51 6 42 0 
QTd mean 44.40 39.20 52.38 37.12 
QTd >60 ms 6 6 36 2 
 
Both these studies shows increased QTc interval parameters in SLE patients. To our 
knowledge it is the first study in India to assess these parameters. These ECG 
changes are found even after excluding patients with baseline ECG abnormalities, 
systemic hypertension, renal failure and electrolyte abnormalities. Subclinical 
atherosclerosis or silent myocarditis might be the probable reason for such QTc  
prolongation in SLE patients. 
In our study we also studied the association between QTc prolongation and disease 
activity (SLEDAI). We found a statistically significant correlation between the two 
parameters. Then we also assessed the QTc interval of these patients during a flare. 
Though there was a positive correlation it was not statistically significant except for 
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severe flare. Like QTc interval we also studied QT dispersion in SLE patients. 
Though there was a difference in mean value between cases and controls, it was not 
statistically significant. 
In the study done by Cardoso et al QT dispersion values were also sign ificantly 
prolonged when compared to controls.
10
 In another study done by Javad Kojuri et al 
124 patients were studied and 20 were excluded. Two groups were made. One with 
high disease activity (SLEDAI>10) and another with low disease activity 
(SLEDAI<10). The QT dispersion value in high disease activity group was 58.31 ± 
18.66 vs. 47.90 ± 17.41 in low disease activity group with a statistical significance 
(P<0.004). They also studied the influence of hydroxychloroquine and steroids but 
found no association but found a significant association between pericarditis, 
pericardial effusion and disease activity.
2
 
QT interval assessment in SLE patients is to detect those with subclinical myocardial 
involvement and to assess the degree of heterogeneity in cardiac repolarisation. 
Hence we can identify the individuals with high cardiac risk, screen and treat them 
aggressively. To our knowledge no previous studies are available which has assessed 
QT interval parameters during a flare. In severe flare we had a significan t 
association between disease activity and QTc interval. Can QTc interval be used as a 
marker to assess disease activity? ECG is quite easy to obtain, interpret and is 
inexpensive. It needs validation with larger studies and has to be compared with 
Echocardiogarphic parameters and other parameters indicative of subclinical 
atherosclerosis and has to be done on a larger cohort with follow up during flares.  
In a study done by Josiane Bourre Tessier et al, anti Ro antibodies and its 
association with corrected QT interval was assessed.  In the pilot study, 150 subjects 
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were studied with anti Ro positivity of 38% and QTc was prolonged in 7.3% of 
subjects. In the second phase 278 subjects were studied and 41% had anti Ro 
positivity and 6.5% had QTc prolongation. In both the pilot and the second study 
there was a significant association between QTc interval parameters  and anti Ro 
antibodies.
4
 
In our study we found a statistically significant differnce in mean QTc interval 
between anti Ro antibody positive and negative individuals. But there was no 
significant correlation between QT dispersion and anti Ro antibody positivity. 
Similarly there was no association between QT interval parameters and anti La 
positivity. 
In our study we calculated CLASI activity and damage index for the 58 patients with 
cutaneous involvement. There was no correlation between SLEDAI and CLASI i.e. 
between systemic activity and cutaneous activity in our study group. We analysed 
individual types of lesions and their correlation with CLASI activi ty and damage 
index. We found a statistically significant correlation between CLASI activity and 
Acute, Subacute and Chronic type of lesions. Similarly CLASI damage index 
correlated with subacute and chronic lesions but not with acute lesions.  
In a study done by Alakes Kumar Kole et al in Kolkata,150 SLE patients were 
studied. 30% had cutaneous lesions as the presenting manifestations. Malar rash was 
the most common (80%), discoid lesion (20%) and subacute lesions the least 
common(3.34%).
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 Our study(n = 100) 
2014 
Salphale P et al (n = 75) 
2011 
Mean CLASI activity 10.88 15.4 
Mean CLASI damage 5.59 6.87 
 
           In the above South Indian study done by Salphale P et al the mean activity 
and damage scores of CLASI were higher compared to our study. They also found 
that the scores were more when all three types of lesions were present together and 
also in patients with extensive skin involvement covering more surface area. The 
damage index was more in patients with a longer disease duration. 
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In a study done by Nilay Kanti Das et al, the various cutaneous manifestations were 
studied to correlate with systemic disease activity. They found that lesions like non 
scarring alopecia, photosensitivity, oral ulcers and malar rash had significant 
correlation.
97
 
In our study most of the patients had elevated ESR. 41% of them had their ESR 
between 26 – 50 mm.hr and another 41% between 51 – 75 mm/hr. Only 14% had 
ESR values above 75 mm/hr. On analyses we found a significant correlation between 
SLEDAI and ESR. Hence, ESR might be used to assess disease activity indirectly.  
In a study done by G Stojan et al, 1865 different patients over 35,373 visits were 
analysed in a large scale cross sectional study. Though there were a lot of 
uncertainities over ESR for assessing disease activity, this study strongly proved the 
association between the two which is in concordance with our study.
69 
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In another large scale study LUMINA, there was a significant correlation between 
ESR and disease activity but had a lot of confounding factors which could influence 
ESR.
72 
Studies done by Mirzayan et al
74
 and Chang et al couldn‟t demonstrate any 
association between ESR and disease activity but another study done by Nasiri et al 
showed a significant association.
69, 73
  
In our study serum uric acid was elevated in most of the patients with a mean value 
of 6.13. It had a statistically significant correlation with disease activity.  To our 
knowledge this is the first study correlating serum uric acid levels with disease 
activity. Other studies done so far have correlated uric acid with lupus nephritis, 
pulmonary hypertension etc.
81,82 
This study was done in a smaller group of SLE patients and has to be done on a 
larger scale and the parameters have to be assessed on repeated visits. Most of the 
patients had high disease activity, as ours was a tertiary referral centre and hence the 
same can‟t be extrapolated to the patients in a community . QT interval assessment 
has its own drawbacks as discussed before. The T waves are quite heterogenous and 
hence assessment of the exact ending of T wave is difficult and prone to errors.   
Similarly there are lot of confounding factors which could influence ESR. Even 
though in our study we could not find any statistical correlation between SLEDAI 
and CLASI, in our centre we found patients with extensive skin lesions had 
significant  major organ involvement. The individual cutaneous lesions and their 
relationship with CLASI, SLEDAI and internal organ involvement has to be studied 
in detail. 
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Conclusion 
 There was a significant difference in mean QTc interval between SLE patients 
and controls. 
 There was a positive correlation between QTc parameters at baseline and 
during flare but was statistically significant only for severe flare.  
 Patients with anti Ro antibody positivity have significant prolongation of QTc 
interval. 
 Patients with high disease activity have significant prolongation of QTc 
interval. 
 There was a significant correlation between ESR and disease activity in SLE.  
 There was a significant correlation between serum uric acid and disease 
activity in SLE. 
 This study emphasizes the increased prevalence of probably a subclinical  
atherosclerosis or myocarditis and hence QTc prolongation in SLE patients 
with high disease activity. 
 Patients with high disease activity and those with anti Ro antibody positivity 
have to be monitored regularly for increased risk of cardiac arrhythmias and 
have to be treated promptly. 
 In a developing country like ours, where it may be not possible to repeat anti 
ds DNA and complements during each flare, parameters like QTc interval, 
ESR and serum Uric acid may be used as surrogate markers to assess disease 
activity. 
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Name    Age  Sex    Date  
 
RCC No. 
 
          H/o. Present Illness 
 
 
 
          Past History 
 
 
          Personal History 
 
 
          Treatment History 
 
 
Family History 
 
 General Examination 
Pallor                   Icterus  
Cyanosis                                         Clubbing   
Lymphadenopathy                       Pedal Edema  
Skin                                    Nails                                      Hair                                    
Weight                               Height                          Waist Circumference         
Pulse Rate             Blood Pressure 
Systemic Examination 
Cardiovascular System   Respiratory System 
 
Abdomen     Central Nervous System 
 
Musculoskeletal System Examination 
 
 
Disease activity scores  
SLEDAI 
CLASI 
Cardiologist opinion 
 
 
 INVESTIGATIONS 
Haemogram 
Hb      TC         DC                             Platelets  ESR  
 
Urine routine                                                       
Bio-Chemistry 
Sugar               Urea             Creatinine             Uric acid 
Bilirubin     AST         ALT      SAP 
Total Proteins  Albumin 
Cholesterol            Triglycerides           LDL            VLDL         HDL 
Urine PCR  
Immunological 
CRP                  RF                                      ANA 
ANa profile 3                     ds DNA     
ACL (IgG & IgM)                                          LAC assay(aPTT & DRVVT)    
C3                                            C4                       DCT 
 
ECHOCARDIOGRAM   
                
Radiography                                                   
  Chest X-Ray                                       
                                         
ELECTROCARDIOGRAM 
 
HEART RATE                                                           RR INTERVAL  
 
RHYTHM  
P WAVE                                                                      PR INTERVAL  
          QRS DURATION  
 
QTc INTERVAL                                                          QT DISPERSION  
 
ST SEGMENT                                                              T WAVE 
 
U WAVE 
 
OTHERS  
 
   
        
SLEDAI (Annexure A2)
 
 
         
Cutaneous Lupus Erythematosus Disease Area and                                    
Severity Index (CLASI) (Annexure A3) 
 
subjects age sex disease duration SLEDAI CLASI Activity CLASI Damage CLASI Total ESR uric acid Anti Ro Anti La QTc cases QTd cases QTc controls QTd controls flare QTc QTd
s1 18 female 4 years 19 0 0 0 70 7.2 positive 465 20 367 20
s2 26 female 1 year 23 20 6 26 70 6.2 positive 450 20 360 20 mild 448 20
s3 23 female 5 years 14 0 0 0 52 6.4 377 40 356 40
s4 18 female 1 year 13 17 10 27 73 6 393 20 408 20 moderate 440 20
s5 19 female 8 months 28 9 0 9 55 3.1 positive 458 40 447 40
s6 22 female 1 year 11 5 0 5 25 5.4 448 20 429 40 severe 459 40
s7 22 female 1 year 25 4 0 4 60 8.5 465 60 420 40 severe 465 40
s8 20 female 6 months 15 18 4 22 48 5.9 positive 447 20 413 60
s9 40 female 4 months 9 4 0 4 66 5.8 390 80 436 60 mild 424 40
s10 30 female 2 months 11 6 9 15 44 4.8 408 60 377 60
s11 38 female 6 months 31 5 0 5 52 7.6 459 20 393 80
s12 25 female 3 years 9 0 0 0 40 6 positive 424 20 383 20 moderate 436 20
s13 34 female 3 months 14 0 0 0 73 7 380 20 371 20
s14 22 female 3 months 10 18 10 28 30 5.8 positive 420 40 425 40
s15 20 female 2 years 7 20 4 24 45 5.6 positive positive 471 60 436 40
s16 23 female 2 years 6 36 8 44 28 4.4 positive 450 40 440 40 moderate 459 40
s17 42 female 3 years 15 0 0 0 48 5.6 412 20 429 20
s18 32 female 1 year 16 0 0 0 55 6.1 440 20 405 60 severe 448 20
s19 53 female 6 months 8 0 0 0 42 6.8 positive 448 80 398 20
s20 17 female 5 months 13 4 0 4 43 5.2 positive 447 20 425 60
s21 40 female 3 years 10 2 0 2 40 3.2 362 80 340 20
s22 18 female 6 months 17 0 0 0 90 6.1 positive 413 40 454 20 severe 426 40
s23 25 female 2 years 25 10 0 10 44 6.2 450 40 425 20
s24 24 female 1 1/2 years 6 13 0 13 36 8.1 positive 459 20 393 40 moderate 440 20
s25 21 female 2 years 35 2 0 2 54 7 469 40 426 40
s26 22 female 3 years 27 3 0 3 30 7.2 447 20 408 40 severe 450 40
s27 28 female 6 months 15 5 0 5 44 5.4 377 60 420 20
s28 18 female 1 1/2 years 10 1 0 1 30 3.4 419 20 347 20
s29 17 female 6 months 18 0 6 6 40 6.6 447 40 371 20
s30 23 female 4 years 29 6 6 12 55 5.8 458 40 383 40
s31 22 female 2 months 24 3 0 3 81 3.8 447 60 360 60
s32 19 female 6 months 44 10 2 12 64 6.4 positive 458 40 347 80
s33 23 female 1 year 17 4 0 4 20 4.2 436 80 356 60 mild 393 40
s34 29 female 6 months 8 2 0 2 46 5.6 positive 408 80 408 40
s35 18 female 5 years 10 20 6 26 36 5.6 450 60 429 40
s36 26 female 1 year 12 16 4 20 73.3 5.3 400 20 436 20
s37 19 male 3 months 21 3 0 3 25 4 positive 439 40 356 40 mild 436 40
s38 24 male 1 year 39 12 2 14 50 6.8 positive 465 40 388 20 severe 461 60
s39 32 female 6 months 13 7 1 8 38 5.6 positive 440 40 377 20
s40 19 female 2 years 12 0 4 4 90 5.6 377 20 360 20
s41 24 female 3 months 14 3 0 3 52 6 positive 448 80 393 40
subjects age sex disease duration SLEDAI CLASI Activity CLASI Damage CLASI Total ESR uric acid Anti Ro Anti La QTc cases QTd cases QTc controls QTd controls flare QTc QTd
s42 21 female 1 month 22 2 0 2 36 3.4 positive 439 40 367 40 moderate 454 60
s43 24 female 5 years 11 2 0 2 20 36 positive 420 60 347 40
s44 48 female 2 years 8 1 0 1 62 6 positive 471 40 360 80
s45 19 female 1 1/2 months 40 12 4 16 40 6.2 458 40 380 60
s46 23 male 4 years 28 1 0 1 52 6.4 436 40 405 60
s47 30 male 4 months 20 4 0 4 56 5.8 pos 436 20 400 60
s48 24 male 8 months 13 1 0 1 35 4.2 408 40 413 40
s49 29 male 1 month 16 0 0 0 70 6.8 pos 436 60 340 40
s50 34 male 4 months 24 0 0 0 55 7.2 pos 465 80 380 20 severe 469 60
s51 19 male 6 months 16 0 0 0 48 5.6 pos 414 20 360 40
s52 21 male 3 months 27 3 0 3 35 6.4 pos 459 60 388 20
s53 23 male 4 months 19 7 2 9 65 6.8 pos 425 40 390 40
s54 26 male 6 months 11 16 3 19 45 5.1 pos positive 450 40 380 60
s55 27 male 6 months 10 4 8 12 50 4.2 pos 436 40 419 40
s56 28 male 1 year 39 12 4 16 140 6.4 pos 461 40 420 20
s57 29 female 2 years 16 20 14 34 44 5.6 388 40 380 40
s58 33 female 3 years 16 1 0 1 56 6.8 447 20 340 40 severe 471 40
s59 26 female 4 years 16 2 0 2 78 6.2 429 80 360 40
s60 19 female 2 years 12 16 8 24 54 5.8 pos 465 80 367 80
s61 19 female 6 months 9 8 22 30 45 4.2 420 80 377 20
s62 21 female 3 months 32 8 0 8 90 7.1 471 60 383 40
s63 28 female 1 year 20 2 0 2 54 6 419 40 371 40 moderate 424 20
s64 45 female 1 year 19 0 0 19 66 6.8 440 60 356 40 moderate 436 40
s65 18 female 6 months 20 0 0 0 32 4.2 401 40 436 60
s66 18 female 4 months 30 20 12 32 75 6.8 447 60 429 40
s67 24 female 2 years 28 2 0 2 60 6 448 60 402 60
s68 21 female 2 years 14 0 0 0 38 5 positive 429 20 424 40
s69 29 female 3 months 34 2 0 2 34 4.4 pos 458 20 436 60
s70 23 female 6 months 41 8 2 10 88 7 pos 454 20 414 40
s71 29 female 1 1/2 years 43 12 4 16 90 6.8 pos 461 40 408 20
s72 30 female 2 years 25 0 0 0 54 6.1 pos 459 20 377 20 mild 440 40
s73 21 female 6 months 29 0 0 0 30 7.2 426 80 393 20
s74 36 female 3 months 23 8 0 8 80 6.8 pos 401 40 383 20
s75 24 female 6 months 29 4 4 8 64 5.4 439 60 388 20
s76 24 male 1 year 21 4 0 4 40 6.4 pos 458 60 419 40 moderate 454 40
s77 28 female 6 months 25 2 0 2 60 5.8 pos positive 481 60 408 20
s78 26 female 1 year 24 6 2 8 54 6 pos 436 40 347 40
s79 24 female 6 months 43 4 0 4 78 6.4 pos 448 20 425 20
s80 22 female 1 1/2 years 32 4.2 360 40 436 20
s81 24 female 6 months 21 1 0 1 134 6.8 pos 471 40 408 20
s82 21 female 7 months 5 14 6 20 80 5.6 pos 450 40 356 60
subjects age sex disease duration SLEDAI CLASI Activity CLASI Damage CLASI Total ESR uric acid Anti Ro Anti La QTc cases QTd cases QTc controls QTd controls flare QTc QTd
s83 29 female 3 years 21 1 0 1 110 4.8 pos 426 40 388 80
s84 21 female 3 years 24 4 0 4 31 7.3 positive 439 40 429 60 severe 440 40
s85 21 female 2 months 36 8 0 8 73 5.7 pos 450 80 367 60
s86 19 female 6 months 22 30 14 44 54 6.2 pos 465 80 380 20
s87 19 female 1 year 23 8 0 8 44 5.8 398 60 401 40
s88 24 female 8 months 15 4 4 60 5.2 pos 426 20 412 20
s89 17 female 1 1/2 years 31 2 0 2 42 6.4 pos 458 20 459 40 moderate 454 60
s90 39 female 1 year 17 6 8 14 30 5.6 400 20 426 20
s91 24 female 4 years 21 1 0 1 60 5.8 388 40 469 40
s92 18 female 2 years 13 18 10 28 44 4.2 pos positive 454 40 454 20
s93 21 female 3 years 23 2 0 2 54 5.6 471 20 475 40
s94 34 female 1 year 11 14 14 28 60 6 positive 459 40 436 20
s95 18 female 3 months 24 8 6 14 74 6.4 426 80 371 60 mild 436 40
s96 32 female 8 months 25 3 0 3 54 5.8 pos 459 60 377 80
s97 28 female 6 months 9 12 10 22 36 4.8 pos 471 80 429 60
s98 26 female 1 1/2 years 34 4 0 4 70 6.8 465 80 383 40 mild 450 40
s99 29 female 2 years 38 10 2 12 80 6.4 414 40 393 40
s100 33 female 6  months 16 12 8 20 65 5.6 420 40 408 40
PATIENT CONSENT FORM 
Title of the Project 
A STUDY ON QT INTERVAL IN PATIENTS WITH SLE AND ITS 
CORRELATION WITH DISEASE ACTIVITY AND AUTOANTIBODIES 
Institution : Department of Rheumatology, 
Madras Medical College, Chennai-600 003.  
Name :     Date  : 
Age  :     IP No : 
Sex  :     RCC No : 
 
The details of the study have been provided to me in 
writing and explained to me in my own language. 
I confirm that I have understood the above study and had 
the opportunity to ask questions. 
I understood that my participation in the study is 
voluntary and that I am free to withdraw at any time, without 
giving any reason, without the medical care that will normally 
be provided by the hospital being affected. 
I agree not to restrict the use of any data or results that arise 
from this study provided such a use is only for scientific purpose(s). 
I have been given an information sheet giving details of 
the study. 
I fully consent to participate in the above study. 
 
 
 
    Signature of Participant  
INFORMATION SHEET 
 We are conducting a study on Systemic Lupus Erythematosus 
among patients attending Government General Hospital, Chennai 
and for that your Co-operation may be valuable to us. 
 The privacy of the patients in the research will be maintained 
throughout the study. In the event of any publication or 
presentation resulting from the research, no personally 
identifiable information will be shared. 
 Taking part in this study is voluntary. You are free to decide 
whether to participate in this study or to withdraw at any time ; 
your decision will not result in any loss of benefits to which you 
are otherwise entitled. 
 The result of the special study may be intimated to you at the 
end of the study period or during the study if anything is found 
abnormal which may aid in the management or treatment.  
 
 
Signature of Investigator               Signature of Participant 
Date          Date 
 
 
MuhŒ¢á x¥òjš got« 
MuhŒ¢á jiy¥ò 
gšYW¥ò mH‰á nehŒ (ÿg°) 
MuhŒ¢á Ãiya« :  ïuhé› fhªâ muR bghJ kU¤Jtkid,  
br‹id-3. 
bga® :    taJ : 
MuhŒ¢á nr®¡if v© :    njâ:  
g§F bgWgt® ïjid ()  F¿¡fî« 
nkny F¿¥ã£LŸs kU¤Jt MŒÉ‹ Étu§fŸ vd¡F 
És¡f¥g£lJ. v‹Dila rªnjf§fis nf£fî«, mj‰fhd jFªj 
És¡f§fis bgwî« thŒ¥gË¡f¥g£lJ. 
eh‹ ï›thŒÉš j‹Å¢irahfjh‹ g§nf‰»nw‹. vªj 
fhuz¤âdhnyh vªj f£l¤âY« vªj r£l á¡fY¡F« c£glhkš eh‹ 
ï›thŒÉš ïUªJ Éy» bfhŸsyh« v‹W« m¿ªJ bfh©nl‹. 
ïªj MŒî r«gªjkhfnth, ïij rh®ªj nkY« MŒî nk‰bfhŸS« 
nghJ« ïªj MŒÉš g§FbgW« kU¤Jt® v‹Dila kU¤Jt 
m¿¡iffis gh®¥gj‰F v‹ mDkâ njitÆšiy vd m¿ªJ bfhŸ»nw‹. 
eh‹ MŒÉš ïUªJ Éy»¡ bfh©lhY« ïJ bghUªJ« vd m¿»nw‹.  
ïªj MŒÉ‹ _y« »il¡F« jftšfisí«, gÇnrhjid 
Koîfisí« k‰W« á»¢ir bjhl®ghd jftšfisí« kU¤Jt® 
nk‰bfhŸS« MŒÉš ga‹gL¤â¡bfhŸsî« mij ãuRÇ¡fî« v‹ KG 
kdJl‹ r«kâ¡»‹nw‹.  
ïªj MŒÉš g§F bfhŸs x¥ò¡bfhŸ»nw‹. vd¡F bfhL¡f¥g£l 
m¿îiufË‹go elªJ bfhŸtJl‹ `ïªj MŒit nk‰bfhŸS« 
kU¤Jt mÂ¡F c©ikíl‹ ïU¥ng‹ v‹W cWâaË»nw‹. vdJ 
clšey« ghâ¡f¥g£lhnyh mšyJ tH¡f¤â‰F khwhd nehŒ¡F¿ 
bj‹g£lhnyh clid mij kU¤Jt mÂÆl« bjÇÉ¥ng‹ v‹W cWâ 
mË¡»nw‹.  
 
 
 
................................ 
g§nf‰ghs® bga® 
................................ 
ifbah¥g«/ ifnuif 
................................ 
njâ 
   
   
................................ 
MuhŒ¢áahsÇ‹ bga® 
................................ 
ifbah¥g« 
................................ 
njâ 
 
MuhŒ¢á jftš jhŸ 
jiy¥ò 
gšYW¥ò mH‰á nehŒ (ÿg°) 
 
br‹id ïuhé›fhªâ muR bghJ kU¤JtidÆš gšYW¥ò mH‰á 
nehŒ (ÿg°) g‰¿a MŒî ï§F eilbgW»wJ. 
Ú§fS« ïªj MuhŒ¢áÆš g§nf‰f ÉU«ò»nwh«. mjdhš 
j§fsJ nehÆ‹ MŒt¿¡ifnah mšyJ á»¢irnah ghâ¥ò V‰glhJ 
v‹gijí« bjÇÉ¤J¡ bfhŸ»nwh«.  
Koîfis mšyJ fU¤Jfis btËÆL«nghnjh mšyJ 
MuhŒ¢áÆ‹ nghnjh j§fsJ bgaiunah mšyJ milahs§fisnah 
btËÆlkh£nlh« v‹gijí« bjÇÉ¤J¡ bfhŸ»nwh«. 
ïªj áw¥ò á»¢irÆ‹ Koîfis MuhŒ¢áÆ‹nghJ mšyJ 
MuhŒ¢áÆ‹ KoÉ‹ nghJ j§fS¡F m¿É¡f¥gL« v‹gijí« 
bjÇÉ¤J¡ bfhŸ»nwh«. 
ïªj MuhŒ¢áÆš g§nf‰gJ j§fSila ÉU¥g¤â‹ ngÇš jh‹ 
ïU¡»wJ. nkY« Ú§fŸ vªneuK« ïªj MuhŒ¢áÆÈUªJ ã‹th§fyh« 
v‹gijí« bjÇÉ¤J¡ bfhŸ»nwh«. 
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g§nf‰ghs® bga® 
................................ 
ifbah¥g«/ ifnuif 
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njâ 
   
   
................................ 
MuhŒ¢áahsÇ‹ bga® 
................................ 
ifbah¥g« 
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njâ 
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